These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25491161)

  • 1. Rate of vision loss in neovascular age-related macular degeneration explored.
    Real JP; Granero GE; De Santis MO; Juarez CP; Palma SD; Kelly SP; Luna JD
    Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1859-65. PubMed ID: 25491161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
    Toth LA; Stevenson M; Chakravarthy U
    Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
    Moisseiev E; Katz G; Moisseiev J; Loewenstein A; Goldstein M; Lomnicky Y; Abend Y; Treister G; Goldenberg D; Levkovitch-Verbin H
    Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL.
    Wickremasinghe SS; Janakan V; Sandhu SS; Amirul-Islam FM; Abedi F; Guymer RH
    Retina; 2016 Jul; 36(7):1331-9. PubMed ID: 26655608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
    Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
    Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
    Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
    Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Brandão EM; Falcão-Reis F; Carneiro AM
    Ophthalmologica; 2014; 232(3):149-55. PubMed ID: 25196907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity.
    Muether PS; Hermann MM; Koch K; Fauser S
    Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):633-7. PubMed ID: 20865421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in vision after retinal pigment epithelium tear following the use of anti-VEGF therapy for age-related macular degeneration.
    Durkin SR; Farmer LD; Kulasekara S; Gilhotra J
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):1-6. PubMed ID: 25749721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration.
    Nguyen V; Daien V; Guymer R; Young S; Hunyor A; Fraser-Bell S; Hunt A; Gillies MC; Barthelmes D;
    Ophthalmology; 2019 Jan; 126(1):64-74. PubMed ID: 30149035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity.
    Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH
    Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.